Date published: 2026-4-29

1-800-457-3801

SCBT Portrait Logo
Seach Input

Ko 143 (CAS 461054-93-3)

5.0(1)
Write a reviewAsk a question

See product citations (21)

Alternate Names:
(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
Application:
Ko 143 is a selective BCRP multidrug transporter inhibitor
CAS Number:
461054-93-3
Purity:
≥99%
Molecular Weight:
469.57
Molecular Formula:
C26H35N3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Ko 143 is a potent and selective ABCG2 (breast cancer resistance protein multidrug transporter, BCRP) inhibitor (EC90 = 26 nM). It displays > 200-fold selectivity over P-gp and MRP-1 transporters. Ko 143 also increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance.


Ko 143 (CAS 461054-93-3) References

  1. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.  |  van Loevezijn, A., et al. 2001. Bioorg Med Chem Lett. 11: 29-32. PMID: 11140726
  2. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.  |  Allen, JD., et al. 2002. Mol Cancer Ther. 1: 417-25. PMID: 12477054
  3. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.  |  Allen, JD., et al. 2003. Cancer Res. 63: 1339-44. PMID: 12649196
  4. Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.  |  Tang, L., et al. 2014. Pharm Res. 31: 847-60. PMID: 24092055
  5. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.  |  Issa, ME., et al. 2014. Anticancer Drugs. 25: 255-69. PMID: 24231527
  6. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.  |  Bakhsheshian, J., et al. 2013. Proc Natl Acad Sci U S A. 110: 20801-6. PMID: 24297888
  7. Role of ABCG2 in transport of the mammalian lignan enterolactone and its secretion into milk in Abcg2 knockout mice.  |  Miguel, V., et al. 2014. Drug Metab Dispos. 42: 943-6. PMID: 24568887
  8. Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation.  |  Jin, JO., et al. 2014. PLoS One. 9: e104753. PMID: 25111504
  9. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.  |  Porcelli, L., et al. 2014. Curr Drug Targets. 15: 1322-30. PMID: 25479544
  10. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).  |  Römermann, K., et al. 2015. Neuropharmacology. 93: 7-14. PMID: 25645391
  11. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines.  |  Dalzell, AM., et al. 2015. Toxicol Lett. 235: 189-98. PMID: 25865432
  12. The Inhibitor Ko143 Is Not Specific for ABCG2.  |  Weidner, LD., et al. 2015. J Pharmacol Exp Ther. 354: 384-93. PMID: 26148857
  13. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.  |  Kim, JH., et al. 2015. BMC Cancer. 15: 504. PMID: 26149077
  14. Interplay of metabolizing enzymes and transporter of xenobiotics.  |  Lim, HY., et al. 2016. Xenobiotica. 46: 25-33. PMID: 26226519
  15. Efflux transport of chrysin and apigenin sulfates in HEK293 cells overexpressing SULT1A3: The role of multidrug resistance-associated protein 4 (MRP4/ABCC4).  |  Li, W., et al. 2015. Biochem Pharmacol. 98: 203-14. PMID: 26291395

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Ko 143, 1 mg

sc-204030
1 mg
$109.00

Ko 143, 10 mg

sc-204030A
10 mg
$261.00